new blood News
Most Popular new blood Story
Regeneron wins rich pact for VEGF trap
Bayer has agreed to pay Regeneron $75 million up front and up to $245 million more in milestone payments in a licensing pact for an experimental VEGF trap therapy for eye diseases. A VEGF trap belongs to the category of drugs known as angiogenesis inhibitors. This therapy blocks the action of vascular endothelial growth factor and prevents the growth of new blood vessels into a tumor. Researchers will develop the …
Read more...Latest Headlines
- October 26, 2007
- August 23, 2007
- August 23, 2007
- October 18, 2006
- July 5, 2006
- May 16, 2006
- April 23, 2006
- November 22, 2005
- October 26, 2005
- September 18, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
